“40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"”
HIMS is undervalued and poised for upside; its platform model captures value from any winning GLP-1 drug, and short-selling pressure will diminish as market cap grows.
I want to talk about the company "Hems & Hers Health". This is another name that is attracting a lot of attention, especially on social media. It's a volatile stock, but it seems to be in a transitional phase, and I'm interested to know your opinion on its role in this area, and your general opinion of the company .